| Objectives : This research is to evaluate the mechanism of Rosuvastatin(Rosu) in reducing the occurrence of myocardial damage in ACS(acute coronary syndrome) patients during the percutaneous coronary intervention(PCI) perioperative period and the clinical efficacy after 30 days of operation by comparing the therapeutic effects of different dosages of Rosuvastatin on the ACS patients undergoing selective in order to provide an objective basis for administering statin drugs in them.Methods:In this research, 60 ACS patients undergoing selective PCI were sampled and randomly divided into three groups: Rosuvastatin low-dosage group(20cases, 5mg/qn, at least per os 1 month), rosuvastatin conventional-dosage group(20 cases, 10mg/qn, at least per os 1 month) and rosuvastatin booster-dosage group(20 cases, 20mg/qn, at least per os 1 month). Detailed clinical data of all patients were recorded after admission, including name, gender, age, history of hypertension or diabetes, smoking,family history, three conventional tests, blood glucose, blood lipids(total cholesterol TC, glycerol triester TG, low-density lipoprotein LDL-C, high-density lipoprotein HLD-C), liver function, renal function, creatine Kinase-MB, hs-c Tn I, NT-pro BNP, PTX3, the number of stents implanted and the number of other vascular-related treatment data. Outcome measures:(1) CK-MB, hs-c Tn I levels of three PCI group patients 24 hours before and after surgery;(2) the plasma PTX3, NT- pro BNP levels of three PCI group patients before PCI, three days and 30 days after PCI respectively;(3) major adverse cardiovascular events(MACEs), including cardiac death, myocardial infarction, revascularization, heart failure and recurrent angina in the three groups of the patients within 30 days after PCI(4) the incidence of adverse drug reactions of the three group patients.Results:1 There was no statistically significant difference between the three groups of the patients in the basic clinical data, including age, gender, history of hypertension or diabetes, smoking, TC, TG, LDL-C, HDL-C, CK-MB, hs-c Tn I, PTX3, NT-pro BNP, angiotensin-converting enzyme inhibitors(ACEI) /angiotensin receptorblocker(ARB), β-blockers, aspirin and clopidogrel applications(P>0.05). 2 The hs-c Tn I and CK-MB as markers of myocardial injury 2.1 The hs-c Tn I level of the three groups of the patients 24 hours after PCI was higher than that before PCI and the difference was statistically significant(P<0.05). The level of the booster-dosage group was significantly lower than that of the low-dosage group or the conventional-dosage group while the level of the conventional dosage group was lower than that of the low-dosage group and the difference was statistically significant(P<0.05). 3 The NT-pro BNP levels 3 days and 30 days after PCI 3.1 The NT-pro BNP levels of three groups of patients 3 days after PCI was higher than that before PCI and the difference was statistically significant(P <0.05). The levels of the low-dosage group, the conventional-dose group and the booster-dose group were slightly higher and the difference was not statistically significant(P>0.05). 3.2 The NT-pro BNP levels of three groups of patients 30 days after PCI increased compared with those before PCI and the difference was statistically significant(P<0.05). The levels of the low-dosage group, the conventional dosage group and the booster dosage group were slightly lower and the difference was not statistically significant(P>0.05). 4 The PTX3 levels of three groups 3 days and 30 days after PCI 4.1 The PTX3 level of three groups 3 days after PCI increased compared with that before PCI and the difference was not statistically significant(P>0.05). The levels of the low-dosage group, the conventional-dosage group, the booster-dosage group were slightly higher and the difference was not statistically significant(P>0.05). 4.2 The PTX3 level of three groups 30 days after PCI decreased compared with that before PCI and the difference was not statistically significant(P >0.05). The levels of the low-dosage group, the conventional-dosage group and the booster-dosage group were slightly lower. The difference was not statistically significant(P>0.05). 5 There was no statistically significant difference in the MACE of three groups within 30 days after PCI(P>0.05). 6. There was no statistically significant difference in the adverse drug reactions of three groups within 30 days after PCI(P>0.05).Conclusions:1 The therapy of booster-dosage of rosuvastatin is superior to conventional-dosage and low-dosage therapy in protecting the heart muscle of the patients with ACS undergoing selective PCI during perioperative period. 2 Rosuvastatin can reduce the NT-pro BNP levels 30 days after PCI in patients with ACS, but there was no statistically significant difference between different dosage groups. 3 Rosuvastatin can reduce the PTX3 levels 30 days after PCI in patients with ACS, but there was no statistically significant difference between different dosage groups and different times. 4 There was no statistically significant difference in MACE between the three groups 30 days after PCI. 5 There were no adverse drug reactions of the three group patients. |
PDF Full Text Request